VA/DoD CLINICAL PRACTICE GUIDELINE FOR OPIOID THERAPY FOR CHRONIC PAIN

DRAFT 3 - DO NOT DISTRIBUTE
VA/DoD Clinical Practice Guideline for Opioid Therapy for Chronic Pain
132. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain--United
States, 2016. JAMA. Apr 19 2016;315(15):1624-1645.
133. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: A
cohort study. Ann Intern Med. Jan 19 2010;152(2):85-92.
134. Bohnert AS, Logan JE, Ganoczy D, Dowell D. A detailed exploration into the association of
prescribed opioid dosage and overdose deaths among patients with chronic pain. Med Care. May
2016;54(5):435-441.
135. Dasgupta N, Funk MJ, Proescholdbell S, Hirsch A, Ribisl KM, Marshall S. Cohort study of the impact
of high-dose opioid analgesics on overdose mortality. Pain Med. Sep 1 2015.
136. Kaplovitch E, Gomes T, Camacho X, Dhalla IA, Mamdani MM, Juurlink DN. Sex differences in dose
escalation and overdose death during chronic opioid therapy: A population-based cohort study.
PLoS One. 2015;10(8):e0134550.
137. Miller M, Barber CW, Leatherman S, et al. Prescription opioid duration of action and the risk of
unintentional overdose among patients receiving opioid therapy. JAMA Intern Med. Apr
2015;175(4):608-615.
138. Goal of label changes: Better prescribing, safer use of opioids. Silver Spring, MD: U.S. Department
of Health and Human Services, Food and Drug Administration; 2013.
139. FDA blueprint for prescriber education for extended-release and long-acting opioid analgesics.
Silver Spring, MD: Department of Health and Human Services, Food and Drug Administration;
2014.
140. Pedersen L, Borchgrevink PC, Breivik HP, Fredheim OM. A randomized, double-blind, doubledummy
comparison of short- and long-acting dihydrocodeine in chronic non-malignant pain. Pain.
May 2014;155(5):881-888.
141. Yu S, Shen W, Yu L, Hou Y, Han J, Richards HM. Safety and efficacy of once-daily hydromorphone
extended-release versus twice-daily oxycodone hydrochloride controlled-release in chinese
patients with cancer pain: A phase 3, randomized, double-blind, multicenter study. J Pain. Aug
2014;15(8):835-844.
142. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug
Evaluation and Research. Abuse-deterrent opioids – evaluation and labeling. Guidance for industry.
2015;
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm
334743.pdf. Accessed September 8, 2016.
143. Ueberall MA, Mueller-Schwefe GH. Safety and efficacy of oxycodone/naloxone vs. Oxycodone vs.
Morphine for the treatment of chronic low back pain: Results of a 12 week prospective,
randomized, open-label blinded endpoint streamlined study with prolonged-release preparations.
Curr Med Res Opin. 2015;31(7):1413-1429.
144. Ahmedzai SH, Nauck F, Bar-Sela G, Bosse B, Leyendecker P, Hopp M. A randomized, double-blind,
active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of
oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer
pain. Palliat Med. Jan 2012;26(1):50-60.
145. Cassidy TA, DasMahapatra P, Black RA, Wieman MS, Butler SF. Changes in prevalence of
prescription opioid abuse after introduction of an abuse-deterrent opioid formulation. Pain Med.
Mar 2014;15(3):440-451.
146. Uberall MA, Mueller-Schwefe GH, Terhaag B. Efficacy and safety of flupirtine modified release for
the management of moderate to severe chronic low back pain: Results of supreme, a prospective
randomized, double-blind, placebo- and active-controlled parallel-group phase iv study. Curr Med
Res Opin. Oct 2012;28(10):1617-1634.
147. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923.
February 2017 Page 186 of 192